Pages that link to "Q39197557"
Jump to navigation
Jump to search
The following pages link to Delivery technologies for genome editing (Q39197557):
Displaying 50 items.
- Manufacturing Cell Therapies Using Engineered Biomaterials. (Q38657159) (← links)
- Roadmap for an early gene therapy for cystic fibrosis airway disease (Q41923573) (← links)
- Intracellular immunization against HIV infection with an intracellular antibody that mimics HIV integrase binding to the cellular LEDGF protein. (Q47152351) (← links)
- Mu transpososome activity-profiling yields hyperactive MuA variants for highly efficient genetic and genome engineering. (Q47205183) (← links)
- Next-Generation Chimeric Antigen Receptor T-Cell Therapy: Going off the Shelf. (Q47215994) (← links)
- Engineering and physical sciences in oncology: challenges and opportunities (Q47244877) (← links)
- In vivo genome editing in animals using AAV-CRISPR system: applications to translational research of human disease (Q47553772) (← links)
- Endoglin and alk1 as therapeutic targets for hereditary hemorrhagic telangiectasia (Q47968783) (← links)
- Personalized Therapeutics and Pharmacogenomics: Integral to Personalized Health Care (Q48160263) (← links)
- CRISPR/Cas9-mediated gene modification and gene knock out in the human-infective parasite Trichomonas vaginalis (Q48267186) (← links)
- Lost in translation: how to upgrade fear memory research (Q48314136) (← links)
- CRISPR-Cas9: a promising genetic engineering approach in cancer research (Q49477344) (← links)
- Commentary: Programmable base editing of A·T to G·C in genomic DNA without DNA cleavage. (Q50204211) (← links)
- Integrated design, execution, and analysis of arrayed and pooled CRISPR genome-editing experiments. (Q52431517) (← links)
- The past and presence of gene targeting: from chemicals and DNA via proteins to RNA. (Q52431809) (← links)
- Non-viral delivery systems for CRISPR/Cas9-based genome editing: Challenges and opportunities. (Q52431943) (← links)
- Metal-organic frameworks for precise inclusion of single-stranded DNA and transfection in immune cells. (Q52609000) (← links)
- Use of the XRCC2 promoter for in vivo cancer diagnosis and therapy. (Q52651261) (← links)
- A Rapid and Facile Pipeline for Generating Genomic Point Mutants in C. elegans Using CRISPR/Cas9 Ribonucleoproteins. (Q54533068) (← links)
- An overview of treatment strategies for Hutchinson-Gilford Progeria syndrome. (Q55004770) (← links)
- Machine Learning To Predict Cell-Penetrating Peptides for Antisense Delivery. (Q55145552) (← links)
- Membrane permeabilizing amphiphilic peptide delivers recombinant transcription factor and CRISPR-Cas9/Cpf1 ribonucleoproteins in hard-to-modify cells. (Q55231818) (← links)
- Application of the CRISPR/Cas9 System to Drug Resistance in Breast Cancer. (Q55309854) (← links)
- Current Challenges in Delivery and Cytosolic Translocation of Therapeutic RNAs. (Q55383414) (← links)
- Targeting of NLRP3 inflammasome with gene editing for the amelioration of inflammatory diseases (Q57022694) (← links)
- Lysosomal storage diseases (Q57060151) (← links)
- Non-Viral Delivery To Enable Genome Editing (Q57065785) (← links)
- Electroporation-mediated genome editing in vitrified/warmed mouse zygotes created by IVF via ultra-superovulation (Q57091740) (← links)
- Arbovirus Infections As Screening Tools for the Identification of Viral Immunomodulators and Host Antiviral Factors (Q57111498) (← links)
- CRISPR/Cascade 9-Mediated Genome Editing-Challenges and Opportunities (Q57177058) (← links)
- Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Therapeutics (Q57282212) (← links)
- All-in-one adeno-associated virus delivery and genome editing by Neisseria meningitidis Cas9 in vivo (Q58324031) (← links)
- Universal intracellular biomolecule delivery with precise dosage control (Q58587940) (← links)
- Activating PAX gene family paralogs to complement PAX5 leukemia driver mutations (Q58739187) (← links)
- Extension of the crRNA enhances Cpf1 gene editing in vitro and in vivo (Q58771152) (← links)
- Stearyl polyethylenimine complexed with plasmids as the core of human serum albumin nanoparticles noncovalently bound to CRISPR/Cas9 plasmids or siRNA for disrupting or silencing PD-L1 expression for immunotherapy (Q59125830) (← links)
- Long-Term Effects of In Vivo Genome Editing in the Mouse Retina Using Campylobacter jejuni Cas9 Expressed via Adeno-Associated Virus (Q59350237) (← links)
- CRISPR/Cas9 for Cancer Therapy: Hopes and Challenges (Q59351134) (← links)
- Nanotechnology approaches to eradicating HIV reservoirs (Q59359574) (← links)
- Intracellular Delivery by Membrane Disruption: Mechanisms, Strategies, and Concepts (Q60342834) (← links)
- CRISPR/Cas9 Genome Editing to Disable the Latent HIV-1 Provirus (Q60954918) (← links)
- Bivalent Ligands for Protein Degradation in Drug Discovery (Q61809000) (← links)
- Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery (Q63246454) (← links)
- Engineering Precision Medicine (Q63431936) (← links)
- Nucleic Acids as a Nature-Inspired Scaffold for Macromolecular Prodrugs of Nucleoside Analogues (Q64271865) (← links)
- Enhanced Genome Editing with Cas9 Ribonucleoprotein in Diverse Cells and Organisms (Q64389471) (← links)
- Versatile Redox-Responsive Polyplexes for the Delivery of Plasmid DNA, Messenger RNA, and CRISPR-Cas9 Genome-Editing Machinery. (Q64941032) (← links)
- Applications of CRISPR-Cas Enzymes in Cancer Therapeutics and Detection (Q89221788) (← links)
- Quantitating Endosomal Escape of a Library of Polymers for mRNA Delivery (Q89462180) (← links)
- Using CRISPR/Cas9 to model human liver disease (Q89624062) (← links)